{"name":"Nguyen, Davis B., M.D.","slug":"nguyen-davis-b-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fibrin Sealant (Artiss)","genericName":"Fibrin Sealant (Artiss)","slug":"fibrin-sealant-artiss","indication":"Hemostasis and tissue adhesion during surgery","status":"marketed"}]}],"pipeline":[{"name":"Fibrin Sealant (Artiss)","genericName":"Fibrin Sealant (Artiss)","slug":"fibrin-sealant-artiss","phase":"marketed","mechanism":"Fibrin Sealant (Artiss) forms a fibrin clot by combining thrombin and fibrinogen to achieve hemostasis and tissue adhesion.","indications":["Hemostasis and tissue adhesion during surgery","Bleeding control in cardiovascular, general, and orthopedic surgical procedures"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}